WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124903
CAS#: 2364345-05-9 (bis)
Description: Opadotin is a potent antitubulin cytotoxic drug-linker.
Hodoodo Cat#: H124903
Name: Opadotin bistrifluoroacetate
CAS#: 2364345-05-9 (bis)
Chemical Formula: C51H84F6N6O16
Exact Mass: 1,150.58
Molecular Weight: 1,151.250
Elemental Analysis: C, 53.21; H, 7.35; F, 9.90; N, 7.30; O, 22.24
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 2364345-05-9 (bis) 1415246-35-3 (free base)
Synonym: Opadotin bistrifluoroacetate; 8HMJ6PB56B; AS-269 DITRIFLUOROACETATE; AS269 DI-TRIFLUOROACETATE; AMBERSTATIN DI-TRIFLUOROACETATE
IUPAC/Chemical Name: (S)-2-(((2R,3R)-3-((S)-1-((13S,16S,19S,20R)-1-(aminooxy)-19-((S)-sec-butyl)-14-hydroxy-13,16-diisopropyl-20-methoxy-12,18-dimethyl-17-oxo-3,6,9-trioxa-12,15,18-triazadocos-14-en-22-oyl)pyrrolidin-2-yl)-1-hydroxy-3-methoxy-2-methylpropylidene)amino)-3-phenylpropanoic acid--2,2,2-trifluoroacetic acid (1/2)
InChi Key: FDBPFIJQKSNPJU-FHTLEIJJSA-N
InChi Code: InChI=1S/C47H82N6O12.2C2HF3O2/c1-12-33(6)42(52(9)46(57)40(31(2)3)50-45(56)41(32(4)5)51(8)21-22-62-23-24-63-25-26-64-27-28-65-48)38(60-10)30-39(54)53-20-16-19-37(53)43(61-11)34(7)44(55)49-36(47(58)59)29-35-17-14-13-15-18-35;2*3-2(4,5)1(6)7/h13-15,17-18,31-34,36-38,40-43H,12,16,19-30,48H2,1-11H3,(H,49,55)(H,50,56)(H,58,59);2*(H,6,7)/t33-,34+,36-,37-,38+,40-,41-,42-,43+;;/m0../s1
SMILES Code: CC[C@]([C@@](N(C([C@](N=C(O)[C@](N(CCOCCOCCOCCON)C)([H])C(C)C)([H])C(C)C)=O)C)([H])[C@@](OC)([H])CC(N1CCC[C@@]1([H])[C@@](OC)([H])[C@@](C(O)=N[C@@](C(O)=O)([H])CC2=CC=CC=C2)([H])C)=O)([H])C.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 1,151.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Skidmore L, Sakamuri S, Knudsen NA, Hewet AG, Milutinovic S, Barkho W, Biroc
SL, Kirtley J, Marsden R, Storey K, Lopez I, Yu W, Fang SY, Yao S, Gu Y, Tian F.
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent
and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric
Cancers. Mol Cancer Ther. 2020 Sep;19(9):1833-1843. doi:
10.1158/1535-7163.MCT-19-1004. Epub 2020 Jul 15. PMID: 32669315.
2: Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, Zhang T, Wei XL, Zhao
HY, Wang DS, Zhao Q, Xiong GZ, Ji YP, Liang XJ, Xia G, Xu RH. Phase 1
multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive
advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med.
2022 Nov 15;3(11):100814. doi: 10.1016/j.xcrm.2022.100814. PMID: 36384091;
PMCID: PMC9729820.
3: Nagaraja Shastri P, Zhu J, Skidmore L, Liang X, Ji Y, Gu Y, Tian F, Yao S,
Xia G. Nonclinical Development of Next-generation Site-specific HER2-targeting
Antibody-drug Conjugate (ARX788) for Breast Cancer Treatment. Mol Cancer Ther.
2020 Sep;19(9):1822-1832. doi: 10.1158/1535-7163.MCT-19-0692. Epub 2020 Jun 4.
PMID: 32499302.
4: Ayyamperumal S, Dj D, Tallapaneni V, Mohan S, S B, Selvaraj J, Joghee NM, Mjn
C. Molecular docking analysis of α-Topoisomerase II with δ-Carboline derivatives
as potential anticancer agents. Bioinformation. 2021 Jan 31;17(1):249-265. doi:
10.6026/97320630017249. PMID: 34393444; PMCID: PMC8340707.
5: Liang XJ, Gong LY, Zhou F, Zhou DM, Zhu JJ. [Pharmacological effects of site
specific conjugated anti-human epidermal growth factor receptor 2-antibody drug
conjugate using unnatural amino acid technology]. Beijing Da Xue Xue Bao Yi Xue
Ban. 2019 Oct 18;51(5):797-804. Chinese. doi:
10.19723/j.issn.1671-167X.2019.05.002. PMID: 31624380; PMCID: PMC7433521.
